In previous clinical studies in Asia, TAS-117 has shown clinical efficacy in PIK3CA-mutated endometrial and ovarian cancers, in breast cancer cases harboring PIK3CA or AKT1 mutations, and in patients with ovarian clear cell carcinoma. This evidence concerns the gene PIK3CA and ovarian cancer.